دورية أكاديمية
أعرض في EDS

Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: A randomized controlled trial.

التفاصيل البيبلوغرافية
العنوان: Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: A randomized controlled trial.
المؤلفون: Fernandes VHR; State University of Campinas Medical School, Campinas, SP, Brazil., Chaves FRP; State University of Campinas Medical School, Campinas, SP, Brazil., Soares AAS; State University of Campinas Medical School, Campinas, SP, Brazil., Breder I; State University of Campinas Medical School, Campinas, SP, Brazil., Kimura-Medorima ST; State University of Campinas Medical School, Campinas, SP, Brazil., Munhoz DB; State University of Campinas Medical School, Campinas, SP, Brazil., Cintra RMR; State University of Campinas Medical School, Campinas, SP, Brazil., Breder JC; State University of Campinas Medical School, Campinas, SP, Brazil., Barreto J; State University of Campinas Medical School, Campinas, SP, Brazil., Nadruz W; State University of Campinas Medical School, Campinas, SP, Brazil., Carvalho LSF; State University of Campinas Medical School, Campinas, SP, Brazil., Quinaglia T; State University of Campinas Medical School, Campinas, SP, Brazil., Arieta CEL; State University of Campinas Medical School, Campinas, SP, Brazil., Sposito AC; State University of Campinas Medical School, Campinas, SP, Brazil. Electronic address: andreisposito@gmail.com.
مؤلفون مشاركون: ADDENDA-BHS2 trial investigators; State University of Campinas Medical School, Campinas, SP, Brazil.
المصدر: Diabetes & metabolism [Diabetes Metab] 2021 Nov; Vol. 47 (6), pp. 101280. Date of Electronic Publication: 2021 Sep 16.
نوع المنشور: Journal Article; Randomized Controlled Trial
اللغة: English
بيانات الدورية: Publisher: Masson Country of Publication: France NLM ID: 9607599 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1780 (Electronic) Linking ISSN: 12623636 NLM ISO Abbreviation: Diabetes Metab Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Paris : Masson, c1996-
مواضيع طبية MeSH: Benzhydryl Compounds*/therapeutic use , Diabetes Mellitus, Type 2*/complications , Diabetes Mellitus, Type 2*/drug therapy , Glucosides*/therapeutic use , Glyburide*/therapeutic use, Retina/*drug effects, Blood Glucose ; Glycated Hemoglobin/analysis ; Humans ; Hypoglycemic Agents/therapeutic use ; Middle Aged ; Treatment Outcome
مستخلص: Aim: In patients with type 2 diabetes mellitus (T2DM) a progressive thinning in the central retinal thickness (CRT) is mainly related to neuroretinal degeneration and occurs before the decline in visual acuity or capillary density. We investigated the change in CRT by optical coherence tomography (OCT) in T2DM patients after 12 weeks of treatment with dapagliflozin or glibenclamide.
Methods: Ninety-seven patients (57 ± 7 years) with T2DM and clinical or subclinical atherosclerosis were randomized 1:1 to dapagliflozin (10 mg/day) or glibenclamide (5 mg/day) on top of metformin XR 1.5 g/day. OCT was obtained in all patients enrolled in the study, both at the time of randomization and at the end of the study.
Results: Baseline and post-treatment values of fasting glucose and glycated hemoglobin were equivalent in the two arms. There was no difference in change in diabetic retinopathy status after therapy. The center subfield thickness changed by +2(6)μm in the dapagliflozin group and by -1(7) μm in the glibenclamide group (P = 0.001).
Conclusion: A short-term treatment with dapagliflozin may increase CRT as compared with equivalent glycemic control with glibenclamide.
Competing Interests: Declaration of Competing Interests None of the authors had competing interests in this trial.
(Copyright © 2021 Elsevier Masson SAS. All rights reserved.)
فهرسة مساهمة: Keywords: Diabetic retinopathy; Optical coherence tomography; SGLT2i; Type 2 diabetes mellitus
المشرفين على المادة: 0 (Benzhydryl Compounds)
0 (Blood Glucose)
0 (Glucosides)
0 (Glycated Hemoglobin A)
0 (Hypoglycemic Agents)
1ULL0QJ8UC (dapagliflozin)
SX6K58TVWC (Glyburide)
تواريخ الأحداث: Date Created: 20210919 Date Completed: 20220322 Latest Revision: 20221207
رمز التحديث: 20221213
DOI: 10.1016/j.diabet.2021.101280
PMID: 34537385
قاعدة البيانات: MEDLINE
الوصف
تدمد:1878-1780
DOI:10.1016/j.diabet.2021.101280